Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN CARLOS, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter …